İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2025 · article

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

ISSN0028-4793
YÖKSİS OpenAlex Açık erişim · green Üst %1
Yıl2025
Atıf120OpenAlex
Atıf106Semantic Scholar · 11 etkili
Yüzdelik%100,0
FWCI81,941,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q1

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıNew England Journal of Medicine
  • Katalog eşleşmesi (ISSN)New England Journal of Medicine
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

BackgroundWhether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. MethodsIn this phase 3, open-label trial, we included patients 18 years of age or older who had an Eastern Cooperative Oncology Group performance-status score of 0 to 2 (range, 0 to 5, with higher numbers indicating greater disability) and who did not have a 17p deletion or TP53 mutation. Patients were randomly assigned, in a 1:1:1 ratio, to receive acalabrutinib–venetoclax (acalabrutinib, cycles 1 to 14; venetoclax, cycles 3 to 14), acalabrutinib–venetoclax–obinutuzumab (as above, plus obinutuzumab, cycles 2 to 7), or chemoimmunotherapy with the investigator’s choice of fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab (cycles 1 to 6). The primary end point was progression-free survival (acalabrutinib–venetoclax vs. chemoimmunotherapy) in the intention-to-treat population, assessed by blinded independent central review. Research Summary Fixed-Duration Acalabrutinib Combinations in Untreated CLL ResultsA total of 867 patients underwent randomization: 291 were assigned to receive acalabrutinib–venetoclax, 286 acalabrutinib–venetoclax–obinutuzumab, and 290 chemoimmunotherapy (of whom 143 received fludarabine–cyclophosphamide–rituximab and 147 bendamustine–rituximab). The median age of the patients was 61 years (range, 26 to 86), 64.5% were men, and 58.6% had unmutated IGHV. Estimated 36-month progression-free survival at a median follow-up of 40.8 months was 76.5% with acalabrutinib–venetoclax, 83.1% with acalabrutinib–venetoclax–obinutuzumab, and 66.5% with chemoimmunotherapy (hazard ratio for disease progression or death with acalabrutinib–venetoclax vs. chemoimmunotherapy, 0.65 [95% confidence interval {CI}, 0.49 to 0.87], P=0.004; for the comparison of acalabrutinib–venetoclax–obinutuzumab with chemoimmunotherapy, P<0.001). Estimated 36-month overall survival was 94.1% with acalabrutinib–venetoclax, 87.7% with acalabrutinib–venetoclax–obinutuzumab, and 85.9% with chemoimmunotherapy. Neutropenia, the most common adverse event of clinical interest of grade 3 or higher, was reported in 32.3%, 46.1%, and 43.2% in the three groups, respectively; death from coronavirus disease 2019 was reported in 10, 25, and 21 patients in the three groups. ConclusionsAcalabrutinib–venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, NCT03836261.)

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

120atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

21
  1. Jennifer R Brown 1
  2. John F Seymour 2
  3. Wojciech Jurczak 3
  4. Andrew Aw 4
  5. Malgorzata Wach 5
  6. Arpad Illes 6
  7. Alessandra Tedeschİ 7
  8. Carolyn Owen 8
  9. Alan Skarbnik 9
  10. Daniel Lysak 10
  11. Ki-Seong Eom 11
  12. Martin Šimkovič 12
  13. Miguel Arturo Pavlovsky 13
  14. Arnon Philip Kater 14
  15. Barbara Eichhorst 15
  16. Kara Miller 16
  17. Veerendra Munugalavadla 17
  18. Ting Yu 18
  19. Marianne de Borja 19
  20. Paolo Ghia 20
  21. MUHİT ÖZCAN ANKARA ÜNİVERSİTESİ 21